Abstract: Provided is a composition comprising a dimethylchalcone derivative for prevention or treatment of metabolic diseases and, more specifically, to a compositioncomprising a derivative of 2?,4?-dihydroxy-6?-methoxy-3?,5?-dimethylchalcone as an active ingredient for the alleviation, prevention, or treatment of various metabolic diseases.

Abstract: The present invention relates to a composition for inducing differentiation into insulin-producing cells, and a method for inducing differentiation into insulin-producing cells. By using a differentiation inducing composition according to an exemplary embodiment or a differentiation inducing method according to an exemplary embodiment, insulin-producing cells can be prepared in a short period by effectively inducing the differentiation of various types of stem cells into insulin-producing cells, and can be mass-produced in a relatively simple manner, and thus a pharmaceutical composition for preventing or treating diabetes mellitus, comprising insulin-producing cells and/or insulin produced thereby, can be provided.

Abstract: The present invention relates to a composition for preventing or treating diabetes mellitus using a 4-component mixture of putrescine, glucosamine, nicotinamide, and a STAT3 inhibitor. It has been confirmed that blood glucose is stably regulated when a compound of the 4-component mixture according to the present invention is injected into the caudal vein of a diabetes mellitus-induced mouse. The compound can be practically and usefully used as a therapeutic agent for diabetes mellitus patients and patients exposed to diabetes mellitus risk.

Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.

Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.

Abstract: A method for predicting the development of type 2 diabetes before the manifestation of its symptoms in a subject, which comprises measuring the mitochondrial DNA(mtDNA) content in peripheral blood of the subject, comparing the measured mtDNA content with that of a normal control, and predicting the increased risk of development of diabetes when the subjects mtDNA content is lower than that of the normal control.